Welcome to Paid Research Studies




  • Condition:   Neuroblastoma
    Intervention:   Other: Gene panel sequencing of tumor specimens
    Sponsors:   New Approaches to Neuroblastoma Therapy Consortium;   Children's Hospital Los Angeles;   The Evan Foundation;   St. Baldrick's Foundation;   Press On Fund;   Rising Tide Foundation
    Recruiting

  • Condition:   Neuroblastoma
    Intervention:   Biological: GM-CSF + Naxitamab
    Sponsor:   Y-mAbs Therapeutics
    Recruiting

  • Condition:   Neuroblastoma
    Interventions:   Drug: Ch14.18;   Biological: NK Cells;   Drug: Lenalidomide
    Sponsors:   New Approaches to Neuroblastoma Therapy Consortium;   Nationwide Children's Hospital;   United Therapeutics
    Recruiting

  • Condition:   Neuroblastoma
    Interventions:   Genetic: GINAKIT Cells;   Drug: Cyclophosphamide;   Drug: Fludarabine
    Sponsors:   Baylor College of Medicine;   Center for Cell and Gene Therapy, Baylor College of Medicine;   Texas Children's Hospital
    Recruiting

  • Condition:   Neuroblastoma Recurrent
    Intervention:   Drug: metronomic therapy
    Sponsor:   University of Cologne
    Recruiting

  • Condition:   Neuroblastoma
    Intervention:   Drug: dinutuximab beta
    Sponsors:   University Medicine Greifswald;   Children's Cancer Research Institute, Austria
    Recruiting

  • Condition:   Neuroblastoma
    Interventions:   Drug: Vincristine;   Drug: Aldesleukin;   Drug: ch14.18/CHO;   Drug: Carboplatin;   Drug: Etoposide;   Drug: Cisplatin;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: G-CSF;   Drug: Busulfan;   Drug: Melphalan
    Sponsor:   St. Anna Kinderkrebsforschung
    Recruiting

  • Condition:   Neuroblastoma
    Intervention:  
    Sponsors:   Columbia University;   Instituto de Tratamento do Câncer Infantil
    Recruiting

  • Condition:   Neuroblastoma
    Interventions:   Drug: Thiotepa;   Drug: Cyclophosphamide;   Drug: Melphalan;   Drug: Etoposide;   Drug: Carboplatin;   Biological: Autologous Stem Cell Infusion;   Biological: Granulocyte colony stimulating factor
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Condition:   Neuroblastoma
    Interventions:   Drug: cyclophosphamide;   Drug: topotecan;   Biological: hu14.18K322A;   Procedure: peripheral blood stem cell harvest;   Procedure: surgical resection;   Drug: cisplatin;   Drug: etoposide;   Drug: doxorubicin;   Drug: vincristine;   Drug: busulfan;   Drug: melphalan;   Biological: peripheral blood stem cell transplantation;   Biological: natural killer cell infusion;   Radiation: radiation therapy;   Biological: GM-CSF;   Biological: G-CSF;   Drug: mesna;   Drug: levetiracetam;   Biological: interleukin-2;   Drug: Isotretinoin;   Device: CliniMACS
    Sponsors:   St. Jude Children's Research Hospital;   Cookies for Kids' Cancer;   CURE Childhood Cancer, Inc.
    Recruiting

  • Condition:   Neuroblastoma
    Interventions:   Biological: iC9.GD2.CAR.IL-15 T-cells;   Drug: Cyclophosphamide;   Drug: Fludarabine
    Sponsor:   UNC Lineberger Comprehensive Cancer Center
    Recruiting

  • Condition:   Neuroblastoma
    Interventions:   Biological: Ex vivo Expanded and Activated Haploidentical Donor NK Cells;   Biological: Hu14.18-IL2
    Sponsors:   University of Wisconsin, Madison;   National Cancer Institute (NCI);   Solving Kids’ Cancer;   Midwest Athletes Against Childhood Cancer, Inc. (MACC Fund);   Wade's Army;   The Catherine Elizabeth Blair Memorial Foundation / GWCF
    Recruiting

  • Condition:   Neuroblastoma
    Interventions:   Biological: Hu3F8;   Drug: GM-CSF;   Drug: Isotretinoin
    Sponsors:   Memorial Sloan Kettering Cancer Center;   Y-mAbs Therapeutics
    Recruiting

  • Conditions:   Relapsed Neuroblastoma;   Refractory Neuroblastoma
    Interventions:   Genetic: C7R-GD2.CART cells;   Drug: Cyclophosphamide;   Drug: Fludarabine
    Sponsors:   Baylor College of Medicine;   Texas Children's Hospital;   Center for Cell and Gene Therapy, Baylor College of Medicine
    Not yet recruiting

  • Condition:   Neuroblastoma
    Interventions:   Drug: Nivolumab;   Drug: Ch14.18/CHO
    Sponsors:   University Hospital Southampton NHS Foundation Trust;   University College London Hospitals NHS Foundation Trust;   University of Wisconsin, Madison;   University Hospital Greifswald;   Solving Kids' Cancer US/EU;   Joining Against Cancer in Kids;   The Band of Parents
    Recruiting

  • Condition:   Neuroblastoma
    Intervention:  
    Sponsor:   Assiut University
    Recruiting

  • Condition:   Neuroblastoma
    Interventions:   Radiation: External beam radiotherapy;   Radiation: proton beam RT
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting

  • Condition:   Neuroblastoma
    Interventions:   Drug: Bevacizumab;   Drug: Temozolomide;   Drug: Irinotecan;   Drug: Topotecan
    Sponsors:   University of Birmingham;   Cancer Research UK;   Roche Pharma AG;   Imagine for Margo
    Recruiting

  • Condition:   Neuroblastoma
    Intervention:   Drug: Metaiodobenzylguanidine (MIBG)
    Sponsor:   University of California, San Francisco
    Available

  • Condition:   Relapsed Neuroblastoma
    Interventions:   Radiation: Cerebral Spinal (CS) radiation;   Radiation: Focal radiotherapy (SRS)
    Sponsor:   Giselle Sholler
    Recruiting

  • Condition:   LOW AND INTERMEDIATE PAEDIATRIC NEUROBLASTOMA AND NEONATAL SUPRARENAL MASSES
    Intervention:   Drug: chemotherapy
    Sponsor:   Instituto de Investigacion Sanitaria La Fe
    Recruiting

  • Condition:   Neuroblastoma (NB)
    Interventions:   Drug: Irinotecan;   Drug: temozolomide;   Biological: Hu3F8;   Drug: GM-CSF
    Sponsors:   Memorial Sloan Kettering Cancer Center;   Y-Mabs, Inc
    Recruiting

  • Condition:   Neuroblastoma
    Interventions:   Drug: Carboplatin;   Biological: Autologous stem cell infusion;   Biological: Granulocyte colony stimulating factor;   Radiation: Radiation therapy;   Drug: Isotretinoin (13-cis-retinoic acid);   Drug: Melphalan;   Drug: Etoposide
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Disseminated Neuroblastoma;   Recurrent Neuroblastoma
    Interventions:   Biological: IL-2;   Biological: GD2Bi-aATC;   Biological: GM-CSF;   Other: laboratory evaluations of immune responses
    Sponsors:   University of Virginia;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Neuroblastoma
    Intervention:   Biological: Hu3F8 With GM-CSF
    Sponsors:   Memorial Sloan Kettering Cancer Center;   Y-mAbs Therapeutics
    Recruiting

  • Condition:   Neuroblastoma Recurrent
    Interventions:   Drug: DFMO;   Drug: Bortezomib
    Sponsors:   Giselle Sholler;   Beat NB Cancer Foundation;   Because of Ezra
    Recruiting

  • Condition:   Neuroblastoma Recurrent
    Interventions:   Drug: Dasatinib;   Drug: Rapamycin;   Drug: Irinotecan;   Drug: Temozolomide
    Sponsor:   University of Regensburg
    Recruiting

  • Condition:   Neuroblastoma
    Interventions:   Biological: adjuvant OPT-821 in a vaccine containing two antigens (GD2L and GD3L) covalently linked to KLH;   Biological: oral β-glucan
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting

  • Condition:   Very High Risk Neuroblastoma
    Interventions:   Radiation: 131I- mIBG;   Drug: Topotecan;   Drug: Thiotepa;   Procedure: Autologous stem cell transplant
    Sponsors:   Gustave Roussy, Cancer Campus, Grand Paris;   SIOPEN;   National Cancer Institute, France
    Recruiting

  • Conditions:   Neuroblastoma;   Cancer
    Interventions:   Procedure: Biopsy;   Drug: Ceritinib;   Drug: Trametinib;   Drug: HDM201;   Genetic: Next Generation Sequencing;   Procedure: Tumor Scans;   Radiation: X-ray;   Procedure: Bone marrow Tests;   Other: Physical Exam;   Other: Eye Exam;   Other: Labs;   Other: Pregnancy Test;   Behavioral: Interviews;   Other: ECG;   Other: Echocardiogram;   Drug: Ribociclib
    Sponsors:   Yael P Mosse;   Novartis Pharmaceuticals;   Foundation Medicine
    Recruiting

  • Conditions:   Neuroblastoma;   Ganglioneuroblastoma
    Intervention:   Radiation: Proton Beam Radiation Therapy
    Sponsors:   Massachusetts General Hospital;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Relapsed Neuroblastoma;   Metastatic Pheochromocytoma
    Interventions:   Drug: 131 I-Metaiodobenzylguanidine (131I-MIBG);   Drug: Potassium iodide solution;   Drug: G-CSF;   Procedure: hematopoietic stem cell infusion
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Neuroblastoma;   High-Risk
    Interventions:   Drug: cyclophosphamide;   Biological: NK cells;   Biological: hu3F8;   Drug: rIL-2
    Sponsors:   Memorial Sloan Kettering Cancer Center;   Y-mAbs Therapeutics
    Recruiting

  • Conditions:   Neuroblastoma;   Pheochromocytoma
    Intervention:   Drug: 131-I-meta-iodobenzylguanidine
    Sponsors:   Northwell Health;   Cohen Children's Medical Center
    Available

  • Conditions:   Neuroblastoma;   Pheochromocytoma
    Intervention:   Drug: 18F-DA
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting

  • Conditions:   Neuroblastoma;   Ganglioneuroblastoma
    Interventions:   Biological: Patient Derived CD171 specific CAR T cells expressing EGFRt (2nd generation T cells);   Biological: Patient Derived CD171 specific CAR T cells expressing EGFRt (3rd generation T cells);   Biological: Patient Derived CD171 specific CAR T cells expressing EGFRt (long spacer 2nd generation T cells)
    Sponsors:   Seattle Children's Hospital;   The Evan Foundation;   Ben Towne Center for Childhood Cancer Research
    Recruiting

  • Conditions:   Relapsed Neuroblastoma;   Metastatic Pheochromocytoma
    Interventions:   Drug: 131 I-Metaiodobenzylguanidine;   Drug: Potassium Iodide;   Drug: G-csf
    Sponsor:   University of Texas Southwestern Medical Center
    Not yet recruiting

  • Condition:   Neuroblastoma
    Interventions:   Radiation: 131I-MIBG;   Drug: Ch14.18 Monoclonal Antibody
    Sponsors:   New Approaches to Neuroblastoma Therapy Consortium;   United Therapeutics
    Recruiting

  • Condition:   Neuroblastoma
    Interventions:   Drug: Lorlatinib;   Drug: Cyclophosphamide;   Drug: Topotecan
    Sponsors:   New Approaches to Neuroblastoma Therapy Consortium;   Pfizer;   University of Southern California;   Solving Kids' Cancer US/EU;   Children's Neuroblastoma Cancer Foundation;   The Band of Parents;   The Evan Foundation;   Wade's Army;   Ronan Thompson Foundation;   The Catherine Elizabeth Blair Memorial Foundation;   Cookies for Kids' Cancer
    Recruiting

  • Conditions:   Osteosarcoma;   Neuroblastoma
    Interventions:   Genetic: GD2 T cells;   Biological: VZV vaccine;   Drug: Fludarabine;   Drug: Cyclophosphamide
    Sponsors:   Baylor College of Medicine;   National Cancer Institute (NCI);   Center for Cell and Gene Therapy, Baylor College of Medicine;   The Methodist Hospital System;   Texas Children's Hospital
    Recruiting

  • Conditions:   Neuroblastoma;   Pheochromocytoma
    Intervention:   Radiation: iobenguane I 131
    Sponsors:   Memorial Sloan Kettering Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Ganglioneuroblastoma;   Recurrent Neuroblastoma;   Refractory Neuroblastoma
    Interventions:   Biological: Dinutuximab;   Drug: Eflornithine;   Drug: Irinotecan;   Biological: Sargramostim;   Drug: Temozolomide
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Neuroblastoma;   Medulloblastoma
    Interventions:   Drug: Nifurtimox;   Drug: Cyclophosphamide;   Drug: Topotecan
    Sponsors:   Giselle Sholler;   Bayer
    Recruiting

  • Condition:   Neuroblastoma
    Interventions:   Radiation: 131I-MIBG;   Drug: Vincristine;   Drug: Irinotecan;   Drug: Vorinostat
    Sponsor:   New Approaches to Neuroblastoma Therapy Consortium
    Recruiting

  • Conditions:   Microbial Colonization;   Neuroblastoma;   Children, Only
    Interventions:   Diagnostic Test: Initial fecal microbiome;   Diagnostic Test: Initial fecal volatile organic compounds;   Diagnostic Test: Initial breath volatile organic compounds;   Diagnostic Test: Microbiome under chemotherapy;   Diagnostic Test: Fecal volatile organic compounds under chemotherapy;   Diagnostic Test: Breath volatile organic compounds under chemotherapy;   Diagnostic Test: Final microbiome;   Diagnostic Test: Final fecal volatile organic compounds;   Diagnostic Test: Final breath volatile organic compounds
    Sponsor:   Medical University of Graz
    Recruiting

  • Conditions:   Neuroblastoma;   Neuroectodermal Tumors;   Neoplasms
    Intervention:   Drug: 131I-MIBG
    Sponsor:   Jubilant DraxImage Inc.
    Recruiting

  • Condition:   Relapsed or Refractory Neuroblastoma
    Interventions:   Genetic: 1RG-CART/m^2 (Dose Level 1);   Genetic: 1RG-CART/m^2 (Dose Level 2);   Genetic: 1RG-CART/m^2 (Dose Level 3);   Genetic: 1RG-CART/m^2 (Dose Level 4);   Drug: Cyclophosphamide;   Drug: Fludarabine;   Genetic: 1RG-CART/m^2 (Dose Level 5)
    Sponsor:   Cancer Research UK
    Recruiting

  • Conditions:   Neuroblastoma;   Osteosarcoma;   Other Solid Tumor Cancers
    Interventions:   Biological: Humanized 3F8 Bispecific Antibody;   Other: Blood draw
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting

  • Conditions:   Ganglioneuroblastoma;   High-Risk Neuroblastoma;   NMYC Gene Amplification
    Interventions:   Biological: Aldesleukin;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Cyclophosphamide;   Drug: Dexrazoxane;   Biological: Dinutuximab;   Drug: Doxorubicin;   Drug: Etoposide;   Radiation: External Beam Radiation Therapy;   Drug: Isotretinoin;   Drug: Melphalan;   Biological: Sargramostim;   Drug: Thiotepa;   Drug: Topotecan;   Drug: Vincristine
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Neuroblastoma;   CNS Metastases;   Leptomeningeal Metastases
    Intervention:   Biological: 131I-omburtamab
    Sponsor:   Y-mAbs Therapeutics
    Recruiting

  • Conditions:   Recurrent Neuroblastoma;   Stage 2A Neuroblastoma;   Stage 2B Neuroblastoma;   Stage 3 Neuroblastoma;   Stage 4 Neuroblastoma;   Stage 4S Neuroblastoma
    Interventions:   Other: Cytology Specimen Collection Procedure;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Neuroblastoma;   Childhood Metastatic Pheochromocytoma;   Paraganglioma
    Interventions:   Drug: 131 I-Metaiodobenzylguanidine (131 I-MIBG);   Drug: 131 I-MIBG
    Sponsor:   Children's Hospital of Philadelphia
    Available

  • Conditions:   Ganglioneuroblastoma;   Localized Resectable Neuroblastoma;   Localized Unresectable Neuroblastoma;   Regional Neuroblastoma;   Stage 4 Neuroblastoma
    Interventions:   Drug: Carboplatin;   Other: Clinical Observation;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Neuroblastoma;   Pheochromocytoma;   Paraganglioma
    Intervention:   Radiation: I-131 MIBG
    Sponsor:   Children's Hospital Medical Center, Cincinnati
    Available

  • Condition:   Neuroblastoma
    Interventions:   Drug: Liquid 13-Cis Retinoic Acid;   Drug: Extracted capsules 13-CRA
    Sponsor:   Nova Laboratories Limited
    Recruiting

  • Conditions:   Ganglioneuroblastoma;   Localized Resectable Neuroblastoma;   Localized Unresectable Neuroblastoma;   Regional Neuroblastoma;   Stage 4 Neuroblastoma;   Stage 4S Neuroblastoma
    Interventions:   Other: Cytology Specimen Collection Procedure;   Other: Laboratory Biomarker Analysis
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Neuroblastoma
    Intervention:   Other: Tumor and Marrow Markers
    Sponsors:   Memorial Sloan Kettering Cancer Center;   Southern Illinois University;   Spanish National Cancer Center;   St. Jude Children's Research Hospital;   Washington University School of Medicine;   University of Texas;   Weill Medical College of Cornell University
    Recruiting

  • Conditions:   Childhood Ganglioneuroblastoma;   Childhood Neuroblastoma;   INRG Stage L2;   INRG Stage M;   INRG Stage MS;   NMYC Gene Amplification;   Recurrent Neuroblastoma
    Interventions:   Biological: Aldesleukin;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Busulfan;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Crizotinib;   Drug: Cyclophosphamide;   Drug: Dexrazoxane Hydrochloride;   Biological: Dinutuximab;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide Phosphate;   Radiation: External Beam Radiation Therapy;   Radiation: Iobenguane I-131;   Drug: Isotretinoin;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Other: Pharmacological Study;   Biological: Sargramostim;   Procedure: Therapeutic Conventional Surgery;   Drug: Thiotepa;   Drug: Topotecan Hydrochloride;   Drug: Vincristine Sulfate
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Opsoclonus Myoclonus Syndrome;   Neuroblastoma
    Interventions:   Drug: Dexamethasone acetate;   Drug: dexamethasone and cyclophosphamide;   Drug: dexamethasone and rituximab
    Sponsor:   Institut Curie
    Recruiting

  • Conditions:   Neuroblastoma;   Sarcoma;   Pediatric Cancer
    Intervention:   Drug: 13C-glucose
    Sponsor:   University of Texas Southwestern Medical Center
    Recruiting

  • Condition:   Relapsed or Refractory Medulloblastoma (MB) (Part A: Also Include Neuroblastoma (NB), Ewing Sarcoma (ES) and Alveolar Rhabdomyosarcoma (ARMS))
    Interventions:   Drug: TB-403 20mg/kg;   Drug: TB-403 50mg/kg;   Drug: TB-403 100mg/kg;   Drug: TB-403 ≤175mg/kg
    Sponsors:   Oncurious NV;   BioInvent International AB;   Beat Childhood Cancer
    Recruiting

  • Conditions:   Neuroendocrine Tumors;   Neuroblastoma;   Pheochromocytoma;   Paraganglioma
    Interventions:   Drug: 177Lu-DOTA-tyr3-OCTREOTATE;   Procedure: Peptide Receptor Radiotherapy (PRRT)
    Sponsors:   Sue O'Dorisio;   Advanced Accelerator Applications
    Not yet recruiting

  • Conditions:   Lymphoma;   Neuroblastoma;   Brain Tumor;   Solid Tumor
    Intervention:   Drug: CUDC-907
    Sponsors:   Dana-Farber Cancer Institute;   Curis, Inc.
    Recruiting

  • Conditions:   Ewing Family of Tumors;   Melanoma;   Neuroblastoma;   Osteosarcoma
    Intervention:  
    Sponsors:   St. Jude Children's Research Hospital;   University of Wisconsin, Madison
    Recruiting

  • Conditions:   Neuroendocrine Tumors;   Meningioma;   Neuroblastoma;   Medulloblastoma
    Interventions:   Radiation: 90Y-DOTA tyr3-Octreotide;   Diagnostic Test: 68Ga-DOTATOC PET Positron Emission Tomography (PET) whole body scan;   Drug: Amino Acids
    Sponsors:   Sue O'Dorisio;   National Institutes of Health (NIH);   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Neuroendocrine Tumors;   Carcinoid Tumors;   Neuroblastoma;   Medulloblastoma
    Intervention:   Drug: 68Ga-DOTATOC PET/CT
    Sponsors:   Sue O'Dorisio;   University of Iowa Foundation
    Recruiting

  • Conditions:   Pediatric Solid Tumor;   Pediatric Lymphoma;   Pediatric Brain Tumor
    Intervention:   Drug: CLR 131
    Sponsor:   Cellectar Biosciences, Inc.
    Recruiting

  • Conditions:   Solid Tumors;   Ewing Sarcoma;   Rhabdoid Tumor;   Rhabdomyosarcoma;   Neuroblastoma;   Medulloblastoma
    Interventions:   Drug: Palbociclib;   Drug: Temozolomide;   Drug: Irinotecan
    Sponsor:   Pfizer
    Not yet recruiting

  • Conditions:   Recurrent or Refractory Solid Tumors;   Ewing Sarcoma;   Rhabdomyosarcoma;   Neuroblastoma;   Osteosarcoma
    Intervention:   Drug: MM-398 (Irinotecan Sucrosofate Liposome Injection) plus cyclophosphamide
    Sponsor:   South Plains Oncology Consortium
    Recruiting

  • Conditions:   Ewing Sarcoma;   Neuroblastoma;   Rhabdomyosarcoma;   Osteosarcoma;   CNS Tumors
    Interventions:   Procedure: Allogeneic HCT;   Drug: Donor NK Cell Infusion
    Sponsor:   Monica Thakar
    Recruiting

  • Conditions:   Congenital Hyperinsulinism;   Neuroblastoma;   Neuroendocrine Tumors;   Parkinson Disease;   Brain Glioma
    Intervention:   Drug: 18F-DOPA
    Sponsors:   University of Alberta;   Alberta Health Services
    Recruiting

  • Conditions:   Sarcoma;   Endocrine Tumors;   Neuroblastoma;   Retinoblastoma;   Renal Cancer
    Intervention:  
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Severe Combined Immunodeficiency;   Malignancy, Hematologic;   Neuroblastoma;   Neoplasm;   Mucopolysaccharidosis I
    Intervention:   Procedure: Venipuncture
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting

  • Conditions:   Endocrine Tumors;   Thyroid Neoplasms;   Parathyroid Neoplasms;   Adrenal Neoplasm;   Neuroblastoma
    Intervention:  
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Malignancies;   Acute Lymphoblastic Leukemia (ALL);   Acute Myeloid Leukemia (AML);   Non-Hodgkin's Lymphoma;   Neuroblastoma
    Interventions:   Drug: chemotherapy;   Drug: venetoclax
    Sponsors:   AbbVie;   Roche-Genentech
    Recruiting

  • Conditions:   Neuroblastoma;   Medulloblastoma;   Typical Teratoid Rhabdoid Tumor;   Embryonal Tumor With Abundant Neuropil and True Rosettes;   Ependymoblastoma;   Medulloepithelioma
    Intervention:   Drug: eflornithine HCl
    Sponsors:   Giselle Sholler;   KidsCure Pharmaceuticals
    Available

  • Conditions:   Congenital Central Hypoventilation Syndrome;   Congenital Central Hypoventilation;   CCHS;   CCHS With Hirschsprung Disease;   CCHS With Neural Crest Tumor;   CCHS With Neuroblastoma
    Intervention:   Other: NIH Toolbox Cognition Battery
    Sponsors:   Debra Weese-Mayer;   Ann & Robert H Lurie Children's Hospital of Chicago;   Seattle Children's Hospital;   Children's Hospital Los Angeles
    Recruiting

  • Conditions:   Neuroblastoma;   Rhabdomyosarcoma;   Ewing Sarcoma Family of Tumors;   Osteosarcoma;   Leukemia;   Central Nervous System Tumor
    Intervention:   Other: Sampling on blood, bone marrow and cerebrospinal fluid
    Sponsor:   Institut Curie
    Recruiting

  • Conditions:   Acute Leukemia;   Adenomatous Polyposis;   Adrenocortical Carcinoma;   AML;   BAP1 Tumor Predisposition Syndrome;   Carney Complex;   Choroid Plexus Carcinoma;   Constitutional Mismatch Repair Deficiency Syndrome;   Diamond-Blackfan Anemia;   DICER1 Syndrome;   Dyskeratosis Congenita;   Emberger Syndrome;   Familial Acute Myeloid Leukemia;   Familial Adenomatous Polyposis;   Fanconi Anemia;   Familial Cancer;   Familial Wilms Tumor;   Familial Neuroblastoma;   GIST;   Hereditary Breast and Ovarian Cancer;   Hereditary Paraganglioma-Pheochromocytoma Syndrome;   Hodgkin Lymphoma;   Juvenile Polyposis;   Li-Fraumeni Syndrome;   Lynch Syndrome;   MDS;   Melanoma Syndrome;   Multiple Endocrine Neoplasia Type 1;   Multiple Endocrine Neoplasia Type 2;   Neuroblastoma;   Neurofibromatosis Type 1;   Neurofibromatosis Type II;   Nevoid Basal Cell Carcinoma Syndrome;   Non Hodgkin Lymphoma;   Noonan Syndrome and Other Rasopathy;   Overgrowth Syndromes;   Pancreatic Cancer;   Peutz-Jeghers Syndrome;   Pheochromocytoma/Paraganglioma;   PTEN Hamartoma Tumor Syndrome;   Retinoblastoma;   Rhabdoid Tumor Predisposition Syndrome;   Rhabdomyosarcoma;   Rothmund-Thomson Syndrome;   Tuberous Sclerosis;   Von Hippel-Lindau Disease
    Intervention:  
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting

  • Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma;   BRAF Gene Mutation;   GNA11 Gene Mutation;   GNAQ Gene Mutation;   Histiocytosis;   HRAS Gene Mutation;   KRAS Gene Mutation;   NF1 Gene Mutation;   NRAS Gene Mutation;   Recurrent Childhood Central Nervous System Neoplasm;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Neuroblastoma;   Refractory Central Nervous System Neoplasm;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma
    Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Selumetinib;   Drug: Selumetinib Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Advanced Malignant Solid Neoplasm;   ALK Fusion Protein Expression;   ALK Gene Mutation;   ALK Gene Translocation;   Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma;   Histiocytosis;   Recurrent Childhood Central Nervous System Neoplasm;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Neuroblastoma;   Refractory Central Nervous System Neoplasm;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   ROS1 Fusion Positive;   ROS1 Gene Mutation;   ROS1 Gene Translocation
    Interventions:   Drug: Ensartinib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Advanced Malignant Solid Neoplasm;   ARAF Gene Mutation;   BRAF Gene Mutation;   GNA11 Gene Mutation;   GNAQ Gene Mutation;   HRAS Gene Mutation;   KRAS Gene Mutation;   MAP2K1 Gene Mutation;   MAPK1 Gene Mutation;   NF1 Gene Mutation;   NRAS Gene Mutation;   Recurrent Ependymal Tumor;   Recurrent Ewing Sarcoma;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Histiocytic and Dendritic Cell Neoplasm;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Central Nervous System Neoplasm;   Recurrent Malignant Germ Cell Tumor;   Recurrent Malignant Solid Neoplasm;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Osteosarcoma;   Recurrent Peripheral Primitive Neuroectodermal Tumor;   Recurrent Rhabdoid Tumor;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Refractory Ependymoma;   Refractory Ewing Sarcoma;   Refractory Glioma;   Refractory Hepatoblastoma;   Refractory Histiocytic and Dendritic Cell Neoplasm;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Central Nervous System Neoplasm;   Refractory Malignant Germ Cell Tumor;   Refractory Malignant Solid Neoplasm;   Refractory Medulloblastoma;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Peripheral Primitive Neuroectodermal Tumor;   Refractory Rhabdoid Tumor;   Refractory Rhabdomyosarcoma;   Refractory Soft Tissue Sarcoma;   Wilms Tumor
    Interventions:   Other: Pharmacokinetic Study;   Drug: Ulixertinib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Advanced Malignant Solid Neoplasm;   RB1 Positive;   Recurrent Childhood Ependymoma;   Recurrent Ewing Sarcoma;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Kidney Wilms Tumor;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Germ Cell Tumor;   Recurrent Malignant Glioma;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Osteosarcoma;   Recurrent Peripheral Primitive Neuroectodermal Tumor;   Recurrent Rhabdoid Tumor;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Refractory Ependymoma;   Refractory Ewing Sarcoma;   Refractory Glioma;   Refractory Hepatoblastoma;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Germ Cell Tumor;   Refractory Malignant Glioma;   Refractory Medulloblastoma;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Peripheral Primitive Neuroectodermal Tumor;   Refractory Rhabdoid Tumor;   Refractory Rhabdomyosarcoma;   Refractory Soft Tissue Sarcoma
    Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Palbociclib;   Other: Pharmacological Study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma;   BRAF NP_004324.2:p.V600X;   Ependymoma;   Ewing Sarcoma;   Hepatoblastoma;   Histiocytosis;   Langerhans Cell Histiocytosis;   Malignant Germ Cell Tumor;   Malignant Glioma;   Osteosarcoma;   Peripheral Primitive Neuroectodermal Tumor;   Recurrent Childhood Central Nervous System Neoplasm;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Neuroblastoma;   Refractory Central Nervous System Neoplasm;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Rhabdoid Tumor;   Rhabdomyosarcoma;   Soft Tissue Sarcoma;   Wilms Tumor
    Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Vemurafenib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Central Nervous System Embryonal Tumor With Rhabdoid Features;   Central Nervous System Embryonal Tumor, Not Otherwise Specified;   Central Nervous System Ganglioneuroblastoma;   Embryonal Tumor With Multilayered Rosettes, C19MC-Altered;   Pineoblastoma;   Primary Central Nervous System Neoplasm;   Recurrent Childhood Central Nervous System Embryonal Neoplasm;   Recurrent Malignant Solid Neoplasm;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Rhabdomyosarcoma;   Refractory Malignant Solid Neoplasm;   Refractory Medulloblastoma;   Refractory Neuroblastoma;   Refractory Rhabdomyosarcoma
    Interventions:   Drug: Adavosertib;   Drug: Irinotecan Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma;   Deleterious ATM Gene Mutation;   Deleterious BRCA1 Gene Mutation;   Deleterious BRCA2 Gene Mutation;   Deleterious RAD51C Gene Mutation;   Deleterious RAD51D Gene Mutation;   Histiocytosis;   Low Grade Glioma;   Malignant Glioma;   Recurrent Childhood Central Nervous System Neoplasm;   Recurrent Childhood Ependymoma;   Recurrent Childhood Malignant Germ Cell Tumor;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Solid Neoplasm;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Osteosarcoma;   Refractory Central Nervous System Neoplasm;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Rhabdoid Tumor;   Wilms Tumor
    Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Olaparib;   Other: Pharmacological Study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Advanced Malignant Solid Neoplasm;   NTRK1 Fusion Positive;   NTRK2 Fusion Positive;   NTRK3 Fusion Positive;   Recurrent Childhood Ependymoma;   Recurrent Childhood Malignant Germ Cell Tumor;   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Glioma;   Recurrent Malignant Solid Neoplasm;   Recurrent Neuroblastoma;   Recurrent Osteosarcoma;   Recurrent Rhabdoid Tumor;   Refractory Central Nervous System Neoplasm;   Refractory Childhood Malignant Germ Cell Tumor;   Refractory Ependymoma;   Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Refractory Glioma;   Refractory Hepatoblastoma;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Glioma;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Rhabdoid Tumor;   Refractory Rhabdomyosarcoma;   Wilms Tumor
    Interventions:   Drug: Larotrectinib;   Drug: Larotrectinib Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Non-Hodgkin Lymphoma;   Malignant Glioma;   Recurrent Central Nervous System Neoplasm;   Recurrent Childhood Ependymoma;   Recurrent Ewing Sarcoma;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Germ Cell Tumor;   Recurrent Malignant Solid Neoplasm;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Osteosarcoma;   Recurrent Peripheral Primitive Neuroectodermal Tumor;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Refractory Central Nervous System Neoplasm;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Germ Cell Tumor;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Rhabdoid Tumor;   Stage III Osteosarcoma AJCC v7;   Stage III Soft Tissue Sarcoma AJCC v7;   Stage IV Osteosarcoma AJCC v7;   Stage IV Soft Tissue Sarcoma AJCC v7;   Stage IVA Osteosarcoma AJCC v7;   Stage IVB Osteosarcoma AJCC v7;   TSC1 Gene Mutation;   TSC2 Gene Mutation;   Wilms Tumor
    Interventions:   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: PI3K/mTOR Inhibitor LY3023414
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma;   FGFR1 Gene Mutation;   FGFR2 Gene Mutation;   FGFR3 Gene Mutation;   FGFR4 Gene Mutation;   Histiocytosis;   Low Grade Glioma;   Malignant Glioma;   Recurrent Central Nervous System Neoplasm;   Recurrent Childhood Ependymoma;   Recurrent Childhood Malignant Germ Cell Tumor;   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Solid Neoplasm;   Recurrent Neuroblastoma;   Recurrent Osteosarcoma;   Refractory Central Nervous System Neoplasm;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Rhabdoid Tumor;   Stage III Soft Tissue Sarcoma AJCC v7;   Stage IV Soft Tissue Sarcoma AJCC v7;   Wilms Tumor
    Interventions:   Drug: Erdafitinib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma;   Childhood Langerhans Cell Histiocytosis;   Histiocytic Sarcoma;   Juvenile Xanthogranuloma;   Malignant Glioma;   Recurrent Central Nervous System Neoplasm;   Recurrent Childhood Ependymoma;   Recurrent Childhood Malignant Germ Cell Tumor;   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Ewing Sarcoma;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Solid Neoplasm;   Recurrent Neuroblastoma;   Recurrent Osteosarcoma;   Recurrent Peripheral Primitive Neuroectodermal Tumor;   Recurrent Rhabdoid Tumor;   Refractory Central Nervous System Neoplasm;   Refractory Childhood Malignant Germ Cell Tumor;   Refractory Ewing Sarcoma;   Refractory Glioma;   Refractory Hepatoblastoma;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Solid Neoplasm;   Refractory Medulloblastoma;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Peripheral Primitive Neuroectodermal Tumor;   Refractory Rhabdoid Tumor;   Refractory Rhabdomyosarcoma;   Rhabdoid Tumor;   Stage III Osteosarcoma AJCC v7;   Stage III Soft Tissue Sarcoma AJCC v7;   Stage IV Osteosarcoma AJCC v7;   Stage IV Soft Tissue Sarcoma AJCC v7;   Stage IVA Osteosarcoma AJCC v7;   Stage IVB Osteosarcoma AJCC v7;   Wilms Tumor
    Interventions:   Procedure: Biopsy;   Procedure: Biospecimen Collection;   Drug: Ensartinib;   Drug: Erdafitinib;   Other: Laboratory Biomarker Analysis;   Drug: Larotrectinib;   Procedure: Mutation Carrier Screening;   Drug: Olaparib;   Drug: Palbociclib;   Other: Pharmacological Study;   Drug: PI3K/mTOR Inhibitor LY3023414;   Drug: Selumetinib Sulfate;   Drug: Tazemetostat;   Drug: Ulixertinib;   Drug: Vemurafenib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Pediatric Cancer;   Solid Tumors;   Rhabdomyosarcoma;   Ewing Sarcoma;   Soft Tissue Sarcomas;   Osteosarcoma;   Neuroblastoma;   Wilms Tumor;   Hepatic Tumor;   Germ Cell Tumors
    Interventions:   Device: Magnetic resonance high intensity focused ultrasound;   Drug: Lyso-thermosensitive liposomal doxorubicin
    Sponsor:   AeRang Kim
    Recruiting

  • Conditions:   Metastatic Melanoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Hodgkin Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Melanoma;   Recurrent Neuroblastoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Osteosarcoma;   Recurrent Rhabdomyosarcoma;   Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Refractory Hodgkin Lymphoma;   Refractory Malignant Solid Neoplasm;   Refractory Melanoma;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Rhabdomyosarcoma;   Stage III Cutaneous Melanoma AJCC v7;   Stage IIIA Cutaneous Melanoma AJCC v7;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7
    Interventions:   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Other: Pharmacological Study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Acute Lymphoid Leukemia;   Lymphoma;   Neuroblastoma;   Hepatoblastoma;   Retinoblastoma
    Interventions:   Biological: GM-CSF;   Biological: G-CSF;   Biological: GM-CSF and G-CSF
    Sponsor:   Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
    Recruiting

  • Conditions:   Thyroid Cancer, Medullary;   Carcinoid Tumor;   Pheochromocytoma;   Paraganglioma;   Insulinoma;   Neuroblastoma
    Intervention:   Drug: [18 F]-6-L-fluorodihydroxyphenylalanine (18F-FDOPA)
    Sponsor:   British Columbia Cancer Agency
    Available

  • Conditions:   Pediatric Solid Tumor;   Germ Cell Tumor;   Retinoblastoma;   Hepatoblastoma;   Wilms Tumor;   Rhabdoid Tumor;   Carcinoma;   Osteosarcoma;   Ewing Sarcoma;   Rhabdomyosarcoma;   Synovial Sarcoma;   Clear Cell Sarcoma;   Malignant Peripheral Nerve Sheath Tumors;   Desmoplastic Small Round Cell Tumor;   Soft Tissue Sarcoma;   Neuroblastoma
    Interventions:   Biological: second generation 4-1BBζ EGFR806-EGFRt;   Biological: second generation 4-1BBζ EGFR806-EGFRt and a second generation 4 1BBζ CD19-Her2tG
    Sponsor:   Seattle Children's Hospital
    Recruiting

  • Conditions:   Neuroendocrine Tumors;   Insulinoma;   Gastrinoma;   Glucagonoma;   Vipoma;   Pheochromocytoma;   Paraganglioma;   Neuroblastoma;   Ganglioneuroma;   Medullary Carcinoma;   Pituitary Adenoma;   Medulloblastoma;   Merkel Cell Carcinoma;   Small-cell Lung Cancer;   Meningioma;   Carcinoid
    Interventions:   Diagnostic Test: 68Ga-DOTATOC PET/CT;   Diagnostic Test: 18F-FDG PET/CT
    Sponsor:   British Columbia Cancer Agency
    Recruiting

  • Conditions:   Retinoblastoma;   Clear Cell Sarcoma;   Renal Cell Carcinoma;   Rhabdoid Tumor;   Wilms Tumor;   Hepatoblastoma;   Neuroblastoma;   Germ Cell Tumors;   Ewings Sarcoma;   Non-rhabdomyosarcoma Soft Tissue Sarcoma;   Osteosarcoma;   Rhabdomyosarcoma
    Interventions:   Drug: Simvastatin;   Drug: Cyclophosphamide;   Drug: Topotecan;   Drug: Myeloid growth factor
    Sponsors:   Emory University;   Children's Healthcare of Atlanta
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia;   Hodgkin Lymphoma;   Non-Hodgkin Lymphoma;   Myelodysplastic Syndrome;   Myeloproliferative Syndrome;   Rhabdomyosarcoma;   Ewing Sarcoma;   Primitive Neuroectodermal Tumor;   Osteosarcoma;   Neuroblastoma
    Interventions:   Procedure: TCRαβ+/CD19+ depleted Haploidentical HSCT;   Drug: Zoledronate
    Sponsor:   University of Wisconsin, Madison
    Recruiting

  • Conditions:   Brain Tumors and/or Solid Tumors Including;   Brain Stem Glioma;   High Grade CNS Tumors;   Ependymoma;   Medulloblastoma;   Craniopharyngioma;   Low Grade CNS Tumors;   Hodgkin Lymphoma;   Non Hodgkin Lymphoma;   Ewing Sarcoma;   Osteosarcoma;   Rhabdomyosarcoma;   Neuroblastoma;   Other
    Intervention:   Drug: Methionine
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting

  • Conditions:   Anaplastic Astrocytoma;   Anaplastic Ependymoma;   Anaplastic Ganglioglioma;   Anaplastic Meningioma;   Anaplastic Oligodendroglioma;   Pleomorphic Xanthoastrocytoma, Anaplastic;   Atypical Teratoid/Rhabdoid Tumor;   Brain Cancer;   Brain Tumor;   Central Nervous System Neoplasms;   Choroid Plexus Carcinoma;   CNS Embryonal Tumor With Rhabdoid Features;   Ganglioneuroblastoma of Central Nervous System;   CNS Tumor;   Embryonal Tumor of CNS;   Ependymoma;   Glioblastoma;   Glioma;   Glioma, Malignant;   Medulloblastoma;   Medulloblastoma; Unspecified Site;   Medulloepithelioma;   Neuroepithelial Tumor;   Neoplasms;   Neoplasms, Neuroepithelial;   Papillary Tumor of the Pineal Region (High-grade Only);   Pediatric Brain Tumor;   Pineal Parenchymal Tumor of Intermediate Differentiation (High-grade Only);   Pineoblastoma;   Primitive Neuroectodermal Tumor;   Recurrent Medulloblastoma;   Refractory Brain Tumor;   Neuroblastoma. CNS;   Glioblastoma, IDH-mutant;   Glioblastoma, IDH-wildtype;   Medulloblastoma, Group 3;   Medulloblastoma, Group 4;   Glioma, High Grade;   Neuroepithelial Tumor, High Grade;   Medulloblastoma, SHH-activated and TP53 Mutant;   Medulloblastoma, SHH-activated and TP53 Wildtype;   Medulloblastoma, Chromosome 9q Loss;   Medulloblastoma, Non-WNT Non-SHH, NOS;   Medulloblastoma, Non-WNT/Non-SHH;   Medulloblastoma, PTCH1 Mutation;   Medulloblastoma, WNT-activated;   Ependymoma, Recurrent;   Glioma, Recurrent High Grade;   Glioma, Recurrent Malignant;   Embryonal Tumor, NOS;   Glioma, Diffuse Midline, H3K27M-mutant;   Embryonal Tumor With Multilayered Rosettes (ETMR);   Ependymoma, NOS, WHO Grade III;   Ependymoma, NOS, WHO Grade II;   Medulloblastoma, G3/G4;   Ependymoma, RELA Fusion Positive
    Interventions:   Drug: Gemcitabine;   Drug: ribociclib;   Drug: sonidegib;   Drug: trametinib;   Biological: filgrastim
    Sponsors:   St. Jude Children's Research Hospital;   Novartis Pharmaceuticals
    Recruiting

  • Conditions:   Diffuse Intrinsic Pontine Glioma;   Brain Tumor, Recurrent;   Solid Tumor, Recurrent;   Neuroblastoma, Recurrent, Refractory;   Ewing Sarcoma, Recurrent, Refractory;   Rhabdomyosarcoma, Recurrent, Refractory;   Osteosarcoma, Recurrent, Refractory;   Rhabdoid Tumor, Recurrent, Refractory
    Intervention:   Drug: Abemaciclib
    Sponsor:   Emory University
    Recruiting

  • Condition:   Mixed Tumor, Malignant
    Intervention:   Drug: BAY806946
    Sponsor:   Bayer
    Recruiting

  • Condition:   Esthesioneuroblastoma, Olfactory
    Intervention:  
    Sponsor:   Ricardo L. Carrau, MD
    Recruiting

  • Conditions:   Adenoid Cystic Carcinoma;   Squamous Cell Carcinoma;   Sinonasal Carcinoma;   Sinonasal Undifferentiated Carcinoma;   Mucoepidermoid Carcinoma;   Schneiderian Carcinoma;   Myoepithelial Carcinoma;   Esthesioneuroblastoma;   Melanoma
    Interventions:   Radiation: Proton radiation therapy;   Radiation: Intensity-modulated radiotherapy
    Sponsors:   Massachusetts General Hospital;   National Institutes of Health (NIH);   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Pediatric Solid Tumors
    Intervention:  
    Sponsors:   St. Jude Children's Research Hospital;   Alex's Lemonade Stand Foundation
    Recruiting

  • Condition:   Cancer
    Interventions:   Drug: Gemcitabine;   Drug: Nab-paclitaxel
    Sponsors:   Emory University;   Celgene Corporation
    Recruiting

  • Condition:   Refractory and/or Relapsed Metastatic Solid Tumors
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Radiation: low dose total body irradiation;   Drug: Melphalan;   Drug: Sirolimus
    Sponsor:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    Recruiting

  • Condition:   Cancer
    Interventions:   Drug: Sirolimus;   Drug: Celecoxib;   Drug: Etoposide;   Drug: Cyclophosphamide
    Sponsor:   Emory University
    Recruiting

  • Condition:   Congenital Central Hypoventilation Syndrome
    Intervention:  
    Sponsors:   Debra Weese-Mayer;   Feinberg School of Medicine, Northwestern University;   The Chicago Community Trust
    Recruiting